<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article106</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/A-HeFT" style="display:block; margin-bottom:10px;">A-HeFT Original</a></li>
<h2><strong>A-HeFT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Iso-Dinitrate Plus Hydralazine in Black Patients with Heart Failure".The New England Journal of Medicine. Year Unknown. Volume(Issue):Pages Unknown.PubMed•Full text•PDF<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcomes<br/>
9Funding<br/>
10Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does the addition of a fixed dose combination of isosorbide dinitrate and hydralazine to standard therapy for heart failure improve outcomes in black patients with advanced heart failure?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
The addition of isosorbide dinitrate plus hydralazine to standard therapy, including neurohormonal blockers, significantly increased survival and improved quality of life among black patients with advanced heart failure.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As a result of the study findings, guidelines may now endorse the combination of isosorbide dinitrate plus hydralazine as part of standard therapy for black patients with advanced heart failure.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Randomized, placebo-controlled, double-blind trial<br/>
- Patients recruited from 161 centers in the United States<br/>
- Enrollment: 1050 black patients with NYHA class III or IV heart failure with dilated ventricles<br/>
- Interventions: Fixed dose of isosorbide dinitrate plus hydralazine vs. placebo, in addition to standard therapy<br/>
- Follow-up: Up to 18 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Black patients aged 18 and older<br/>
- NYHA class III or IV heart failure for at least three months<br/>
- Left ventricular ejection fraction ≤35% or &lt;45% with increased left ventricular internal end-diastolic diameter<br/>
- Stable doses of standard therapy for heart failure, including neurohormonal blockers<br/>
<br/>
Exclusion Criteria:<br/>
- Acute myocardial infarction, acute coronary syndrome, or stroke within the preceding three months<br/>
- Cardiac surgery or intervention within the preceding three months<br/>
- Significant valvular disease, hypertrophic or restrictive cardiomyopathy, uncontrolled hypertension, and other specific cardiac conditions<br/>
- Pregnancy, nursing, not using effective contraception if of childbearing age<br/>
- Life expectancy-limiting illness other than heart failure<br/>
<br/>
Baseline Characteristics:<br/>
- Mean age, gender distribution, and baseline comorbid conditions were balanced between the two groups<br/>
<br/>
<h2><strong>Interventions:</strong></h2><br/>
- Fixed-dose combination of isosorbide dinitrate and hydralazine or placebo<br/>
- Initially one tablet containing either 37.5 mg of hydralazine hydrochloride and 20 mg of isosorbide dinitrate or placebo three times daily<br/>
- Increased to two tablets three times daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes:<br/>
- Primary endpoint was a composite score consisting of death from any cause, a first hospitalization for heart failure, and change in quality of life<br/>
<br/>
Secondary Outcomes:<br/>
- Individual components of the primary composite score<br/>
- Cardiovascular death<br/>
- Total number and days of hospitalization<br/>
- Quality of life over the trial<br/>
- Unscheduled healthcare visits<br/>
- Change in B-type natriuretic peptide level<br/>
- Need for cardiac transplantation<br/>
- Change in left ventricular ejection fraction, internal diastolic dimension, and wall thickness<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was funded by NitroMed.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The additional details, appendix, and specific author affiliations are available with the full text of the article.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
